Association between NSAIDs use and adverse clinical outcomes among adults

hospitalised with COVID-19 in South Korea: A nationwide study

Han Eol Jeong MPH, 1, † Hyesung Lee MS, 1, † Hyun Joon Shin MD, 2 Young June Choe MD, 3

Kristian B. Filion PhD, 4,5 Ju-Young Shin PhD 1,6

†These authors contributed equally to this work as co-first authors

¹ School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea

² Division of General Internal Medicine, Department of Medicine, Brigham and Women's

Hospital, Department of Global Health and Social Medicine, Harvard Medical School, Boston,

MA, USA.

³ Division of Infectious Diseases, Department of Social and Preventive Medicine, Hallym

University College of Medicine, Chuncheon, Gangwon-do, South Korea

⁴ Departments of Medicine and Epidemiology, Biostatistics and Occupational Health, McGill

University, Montreal, Quebec, Canada.

⁵ Centre for Clinical Epidemiology, Lady Davis Institute, Montreal, Quebec, Canada.

⁶ Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University,

Seoul, South Korea

Word count (summary): 305

Word count (main text): 2,974

Corresponding author:

Dr Ju-Young Shin

School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon,

Gyeonggi-do 16419, South Korea

Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, 81

Irwon-ro, Gangnam-gu, Seoul 06351, South Korea

Tel: +82-31-290-7702; E-mail: shin.jv@skku.edu

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) may exacerbate COVID-

19 and worsen associated outcomes by upregulating the enzyme that SARS-CoV-2 binds to

enter cells. However, to our knowledge, no study has examined the association between NSAID

use and the risk of COVID-19-related outcomes among hospitalised patients.

METHODS: We conducted a population-based cohort study using South Korea's nationwide

healthcare database, which contains data of all subjects who received a test for COVID-19

(n=69,793) as of April 8, 2020. We identified a cohort of adults hospitalised with COVID-19,

where cohort entry was the date of hospitalisation. NSAIDs users were those prescribed

NSAIDs while hospitalised and non-users were those not prescribed NSAIDs. Our primary

outcome was a composite of death, intensive care unit admission, mechanical ventilation use,

and sepsis; secondary outcome was cardiovascular or renal complications. We conducted

logistic regression analysis to estimate adjusted odds ratio (aOR) with 95% confidence

intervals (CI) for the risk of these outcomes associated with NSAIDs users versus non-users,

using propensity score-inverse probability of treatment weighting to minimize potential

confounding. In sensitivity analyses, we compared NSAIDs to paracetamol (acetaminophen)

to minimize confounding by indication.

FINDINGS: Of 1,824 adults hospitalised with COVID-19 (mean age 44.7 years; female 59%),

285 were NSAIDs users and 1,539 were non-users. Compared with non-users, NSAIDs users

were associated with increased risks of the primary composite outcome (aOR 1.54, 95% CI

1.11-2.15) and cardiovascular or renal complications (aOR 2.64, 95% CI 1.67-4.16). The

association with primary outcome remained consistent when comparing NSAIDs to

paracetamol (aOR 1.31, 95% CI 0.89-1.95).

INTERPRETATION: Use of NSAIDs, compared with non-use, is associated with worse

outcomes among hospitalised COVID-19 patients. While awaiting the results of confirmatory

2

studies, we suggest NSAIDs be used with caution as the harms associated with their use may outweigh their benefits in this population.

INTRODUCTION

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic. Safety concerns on nonsteroidal anti-inflammatory drugs (NSAIDs) were raised as its use may exacerbate COVID-19 by upregulating angiotensin-converting enzyme 2 (ACE2) expressions, she the enzyme which SARS-CoV-2 binds to enter cells. In addition, NSAIDs inhibit cyclooxygenase (COX), which could be involved in the pathogenesis of viral infections to result in tissue damage. These concerns are supported by a recent case report of four young COVID-19 patients who developed serious infectious complications following NSAIDs use. The Health Minister of France recommended that paracetamol (acetaminophen) be used as first-line antipyretic agents over NSAIDs.

The US Food and Drug Admnistration,⁹ European Medicine Agency,¹⁰ and Australia's Therapeutic Goods Admnistration¹¹ also stated that the concerns on NSAIDs are anchored on insufficient evidence and thus, current clinical practice should not be changed till further evidence becomes available. This position is supported by a recent systematic review of randomised trials and observational studies of respiratory viral infections, which concluded that there is currently no evidence to support that NSAIDs are harmful with respect to COVID-19.¹² Despite the widespread use of NSAIDs, there is currently no published observational study that specifically assessed the association between NSAIDs use and clinical outcomes among COVID-19 patients.

This cohort study therefore aimed to examine the association between NSAIDs use, compared to non-use, and worsened clinical outcomes among adults hospitalised with COVID-19 using South Korea's nationwide healthcare database containing all COVID-19 patients.

METHODS

Data source

We used the Health Insurance Review and Assessment Service (HIRA) database of South Korea, provided as part of the #OpenData4Covid19 project which is a global research collaboration on COVID-19 jointly hosted by Ministry of Health and Welfare of Korea and HIRA.¹³ In brief, the South Korean government released the world's first de-identified COVID-19 nationwide patient data on March 27, 2020. Owing to South Korea's National Health Insurance system, which is the universal single-payer healthcare provider covering the entire Korean population of 50 million, and its fee-for-service reimbursement system, the database includes information from both inpatient and outpatient settings.

The HIRA COVID-19 database contains data of all subjects who received a test for COVID-19 as of April 8, 2020, linked to their administrative healthcare data from the previous 3 years (January 1, 2017 to April 8, 2020). The HIRA COVID-19 database includes anonymized patient identifiers, sociodemographic characteristics, healthcare utilization history, diagnoses (International Classification of Diseases, 10th Revision; ICD-10), and drug prescription information (national drug chemical code, prescription date, day's supply, dosage, route of administration). The national drug chemical codes used in South Korea are based on the drug's active chemical ingredient, and are mapped to the Anatomical Therapeutic Chemical (ATC) classification codes (Supplementary Material 1).¹⁴

This study was approved by the Institutional Review Board of Sungkyunkwan University (SKKU 2020-03-012) and obtaining informed consent was waived by the board.

Study design and participants

From 69,793 subjects who received a diagnostic test for COVID-19 between January 1, 2020 to April 8, 2020, there were 5,707 patients who tested positive for COVID-19;

confirmed cases (Figure 1). The presence of COVID-19 was defined by positive findings on Korean Ministry of Food and Drug Safety approved diagnostic tests that used the reverse transcription polymerase chain reaction method targeting the RNA-dependent RNA polymerase, N, and E genes. Confirmed COVID-19 cases were patients with positive test results with a recorded diagnosis of COVID-19, defined using domestic codes (Supplementary Material 2).

Of 5,707 confirmed cases, this population-based cohort study included 1,824 adults (aged ≥19 years) hospitalised with COVID-19 between January 20, 2020 (eg, when the first patient was admitted) and April 8, 2020 in South Korea. In South Korea, patients diagnosed with COVID-19 are required to be admitted to hospital if they are symptomatic, and they remain hospitalised until fully recovered from COVID-19. With the HIRA COVID-19 database covering all Koreans, our study enrolled all inpatients who were hospitalised for COVID-19, and cohort entry was defined as the date of incident COVID-19 hospitalisation (Figure 1).

Exposure to NSAIDs

We used inpatient prescription records from the HIRA database to ascertain exposure after cohort entry among hospitalized COVID-19 patients. We included both oral and intravenous formulations of NSAIDs (aceclofenac, diclofenac, etodolac, fenoprofen, flurbiprofen, dexibuprofen, ibuprofen, ibuproxam, ketoprofen, dexketoprofen, ketorolac, meloxicam, naproxen, piroxicam, celecoxib, polamcoxib, etoricoxib; aspirin was not included as NSAIDs) (Supplementary Material 2).

After being hospitalised with COVID-19, a patient prescribed NSAIDs was classified as NSAIDs users and was followed-up from the date of the first NSAIDs prescription. Patients were classified as non-users when no prescription record of NSAIDs was present after being

6

hospitalised with COVID-19. Patients were followed-up from cohort entry to the earliest of date of outcome occurrence or end of the study period (April 8, 2020).

Outcomes

Our primary outcome was a composite of death, intensive care unit (ICU) admission, mechanical ventilation use, and sepsis. Secondary outcome was cardiovascular or renal complications (myocardial infarction, stroke, heart failure, acute renal failure). We defined outcomes using in-hospital ICD-10 diagnostic codes and procedures using the national procedure coding system (Supplementary Material 2).

Potential confounders

We assessed sociodemographic and clinical factors considered to be associated with NSAIDs use and risk of the outcomes of interest. For sociodemographic factors, we assessed age, sex, and health insurance type (national health insurance, medical aid) at cohort entry; age was grouped into 10-year bands. Clinical variables included comorbidities and use of comedications assessed in the year before cohort entry using inpatient and outpatient data. The following comorbidities were defined using ICD-10 diagnostic codes: hypertension, hyperlipidaemia, diabetes mellitus, malignancy, asthma, chronic obstructive pulmonary disease, atherosclerosis, chronic renal failure, chronic liver disease, rheumatoid arthritis, osteoarthritis, gastrointestinal conditions. We used the expanded benefit coverage codes in addition to diagnosis codes to define malignancy to minimize false positives. Use of comedications were defined using ATC codes and the following medications were included: angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor II blockers (ARBs), β-blockers, calcium channel blockers, diuretics, nitrates (Supplementary Material 2).

Statistical analysis

Baseline sociodemographic and clinical characteristics were summarised for NSAIDs users and non-users using counts and proportions or mean with standard deviation for categorical or continuous variables, respectively. We calculated the absolute standardised difference (aSD) in proportion between NSAIDs users and non-users to determine whether important imbalances were present between groups; aSD ≥0.1 were considered important.

We estimated the cumulative incidence of the primary and secondary composite outcomes among NSAIDs users versus non-users. We used three outcome models using logistic regression to estimate odds ratio (OR) and corresponding 95% confidence intervals (CIs) of the association of interest. The first model was unadjusted. The second model included all covariates described above as covariates. The third model, considered our primary analysis, was adjusted for all potential confounders and weighted by propensity scores (PS) using the inverse probability of treatment weight (IPTW) approach.¹⁷ The PS, or probability of receiving NSAIDs, was estimated using multivariable logistic regression analysis, where age, sex, health insurance type, comorbidities (hypertension, hyperlipidaemia, diabetes mellitus, malignancy, asthma, chronic obstructive pulmonary disease, atherosclerosis, chronic renal failure, chronic liver disease, rheumatoid arthritis, osteoarthritis, gastrointestinal conditions) and use of comedications (ACE inhibitors, ARBs, β-blockers, calcium channel blockers, diuretics, nitrates) were included in the model. The c-statistic value was used to determine model discrimination, with a value between 0.6 and 0.8 considered adequate to predict treatment status based on covariates included. 18 The IPTW approach involves weighting the inverse probability of receiving NSAIDs (1/PS for NSAIDs, and 1/(1-PS) for non-user groups).

Subgroup analyses

In subgroup analyses, we conducted sex- and age-stratified analyses, with age

classified into three groups (<45, 45-65, ≥65 years), for the risk of the primary outcome associated with NSAIDs use. In addition, we stratified by route of administration (oral versus intravenous) and by history of hypertension, hyperlipidaemia, or diabetes mellitus.

Sensitivity analyses

Head-to-head comparison of NSAIDs versus paracetamol

We conducted two sensitivity analysis to determine the robustness of our findings. First, we compared NSAIDs users to paracetamol users to minimize confounding by indication. Paracetamol and propacetamol (prodrug of paracetamol used in South Korea) were included in the paracetamol user group, where both oral and intravenous formulations were included (Supplementary Material 2). Patients prescribed paracetamol only after cohort entry were classified as paracetamol users and were followed-up from the date of the first paracetamol prescription.

Risk of adverse clinical outcomes when extending to non-hospitalised patients

Second, we repeated our entire analyses in all adult patients diagnosed with COVID-19, including those not hospitalised, to investigate whether our findings are generalisable to non-hospitalised patients; hospitalised patients would have different health status and susceptibility to deteriorated clinical outcomes when compared to those not hospitalised. All statistical analyses were performed using the SAS Enterprise Guide software (version 6.1).

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author (JYS) had full access to all the data in the study and had final responsibility for the decision to submit for publication.

9

RESULTS

Of 1,824 adults hospitalised with COVID-19 in South Korea, there were 285 NSAIDs users (16%) and 1,539 non-users (84%). NSAIDs users were older than non-users (mean age 54.4 years versus 48.0 years, aSD 0.47), and had less females (56% versus 59%; aSD 0.07). Except for history of renal failure, NSAID users had more history of comorbidities and use of co-medications compared to non-users (Table 1).

From 75 episodes of primary outcome, there were 56 (cumulative incidence 3.6%) and 19 (6.7%) episodes in NSAIDs users and non-user, respectively. Compared to non-users, NSAIDs users were associated with an 54% increased risk of primary outcome (aOR 1.54, 95% CI 1.11-2.15), which included death, ICU admission, mechanical ventilation use, or sepsis. For secondary outcome, there were 44 episodes of cardiovascular or renal complications (NSAIDs users: 29, 1.9%; non-users: 15, 5.3%). Risk of cardiovascular or renal complications was elevated with NSAIDs users (aOR 2.64, 95% CI 1.67-4.16) compared to non-users (Table 2).

Results of subgroup analyses for primary outcome found no statistically significant interaction between NSAIDs users and various subgroups of NSAIDs formulations (oral, intravenous), age group (<45, 45-65, ≥65 years), sex, and history of hypertension, hyperlipidaemia, and diabetes mellitus (Figure 2).

Findings from sensitivity analyses remained largely consistent with our findings, where the effect estimate for primary outcome associated with NSAIDs users was moderately attenuated compared to paracetamol users (aOR 1.31, 95% CI 0.89-1.95) When including all confirmed cases of COVID-19 (n=5,358), the risk of primary outcome associated with NSAIDs users as compared with non-users was analogous to that of hospitalised patients (aOR 1.67, 95% CI 1.25-2.25) (Figure 3).

DISCUSSION

To the best of our knowledge, this is the first population-based cohort study to have investigated the concerns implicated with NSAIDs use in patient with COVID-19. From 1,824 adults hospitalised with COVID-19 in South Korea, NSAIDs users, as compared with non-users, were associated with an 54% increased risk of primary outcome comprised of death, ICU admission, mechanical ventilation use, or sepsis (aOR 1.54, 95% CI 1.11-2.15). Moreover, the risk of cardiovascular or renal complications were further elevated in NSAIDs users (aOR 2.64, 95% CI 1.67-4.16) compared to non-users. The association with primary outcome remained largely consistent when NSAIDs users were compared with paracetamol users (aOR 1.31, 95% CI 0.89-1.95). In being the first human study, we provide novel evidence that empirically verified the association between worsened clinical outcomes and NSAIDs users.

To date, there is no evidence present on the safety of NSAIDs in COVID-19 patients. Although studies on the risk of primary outcome associated with NSAIDs were unavailable, our findings were consistent when making an indirect comparison to patients with acute respiratory infections or community-acquired pneumonia. A survey from regional pharmacovigilance centres in France reported 386 cases of serious infectious complications resulting in hospitalisations or death among patients who received NSAIDs (ibuprofen, ketoprofen) for acute respiratory infections. However, causality assessment was not conducted to ascertain the association between NSAIDs use and such complications. Moreover, a systematic review of observational studies found an increased risk of pleuropulmonary complications, disseminated infection, abscess, prolonged illness, delays in antibiotic prescriptions associated with NSAIDs in patients with community-acquired pneumonia. 20,21 Likewise, NSAIDs use could have further aggravated the adverse outcomes from SARS-CoV-2 pneumonia.

Our findings showed a particularly increased risk of cardiovascular or renal

complications associated with NSAIDs users (aOR 2.64, 95% CI 1.67-4.16) compared to non-users. Similar to the primary outcome, there were also no direct evidence present on the risk of secondary outcome associated with NSAIDs in COVID-19 patients. However, our results were consistent to two case-crossover studies from patients with acute respiratory infections, which found that NSAIDs use, as compared with non-use, was associated with increased risks of ischemic stroke (aOR 2.27, 95% CI 2.00-2.58) or myocardial infarction (aOR 3.41, 95% CI 2.80-4.16).^{22,23} In addition to the established risks of myocardial infarction and stroke associated with NSAIDs use in the general population, ^{24,25} our findings seem to be plausible which showed an elevated risk of cardiovascular complications with NSAIDs use in COVID-19 patients. Moreover, use of NSAIDs that result in nephrotoxicity, ^{26,27} may be more common among those seriously affected by COVID-19, in which health conditions could be further exacerbated by fever and dehydration.

The underlying pathogenic link between NSAIDs and COVID-19 is yet to be elucidated. However, one animal study found increased ACE2 expressions with NSAIDs (ibuprofen),²⁸ where ACE2 is expressed in various organs such as the lung, heart, and kidneys.^{4,29,30} Thus, ACE2 upregulation induced by NSAIDs could theoretically heighten the infectivity of SARS-CoV-2 to worsen clinical outcomes; multiple organ failure in severe cases. In addition to the ACE2 mechanism, other hypothetical mechanisms were also suggested. NSAIDs could aggravate infections by upregulating COX-2 in activated B lymphocytes to interfere with antibody productions,³¹ or by selectively inhibiting interferon-γ productions that are vital for immunity against foreign pathogens.³² However, with inconsistent findings from animal studies and the precise biological mechanisms yet to be understood, it remains unclear as to whether these findings are readily transferable to humans.

We confirmed the validity of our findings in terms of confounding by indication (Figure 3). Confounding by indication is a bias that may occur when the indication of the study

drug is a predictor of the outcome.³³ This bias typically arises when comparing drug users with non-users. Our main analysis which compared NSAIDs users to non-users, may have been subject to potential confounding by indication. This is because if NSAIDs users may have already had worse prognosis than non-users at baseline, the estimated association between our primary outcome and NSAIDs users may have been overestimated. Thus, we selected paracetamol and compared it with NSAIDs as these drugs have overlapping indications. In comparing paracetamol users to NSAIDs users, we expect to have minimized the impact of confounding by indication and in addition the differences in baseline characteristics. In the sensitivity analysis, we found overall consistent results when comparing NSAIDs users to paracetamol users. Thus, we believe our findings were not subject to confounding by indication.

Our study has several strengths. To our knowledge, this is the first population-based study conducted using all hospitalised patients with COVID-19 to assess an unresolved safety issue of NSAIDs. Moreover, we used a nationwide healthcare database of South Korea that includes information on healthcare utilization of all COVID-19 cases as of April 8. Therefore, our findings provide practical evidence with high representativeness in a real-world setting. Second, our study is unlikely to have been affected by exposure misclassification. According to the fee-for-service reimbursement system in South Korea, all information of inpatient and outpatient prescriptions is available for exposure assessment. Thus, the HIRA database allowed for a highly accurate exposure ascertainment during periods of hospitalisations. 14,34 Last, our findings were consistent in sensitivity analyses that compared NSAIDs users to paracetamol users, suggesting that our study was not subject to confounding by indication.

Our study also has some limitations. First, outcome misclassification based on diagnosis code is possible. However, as for validity, the records of in-hospital deaths are believed to have no errors, while the validity of procedure codes to define ICU admission or mechanical ventilation use are also expected to be high; these codes are used for reimbursement

processes by the health insurance authority. Also, the positive predictive value of diagnosis codes between claims data and electronic medical records was previously reported to be 82%, 35 and we believe its validity to be greater as we restricted to hospitalised patients receiving close monitoring. Second, our findings may have underestimated the association between NSAIDs users and clinical outcome due to depletion of susceptible, ³⁶ as we included prevalent users of NSAIDs; our study would not include patients who already experienced adverse outcomes following NSAIDs use (susceptible). However, NSAIDs are known to be used intermittently on an "as needed" basis in the general population. As for patients with rheumatoid arthritis or osteoarthritis, who use NSAIDs chronically, there were no significant imbalances in the proportion of these comorbidities between NSAIDs users and non-users. Furthermore, we adjusted for any remaining imbalance in baseline characteristics by using the IPTW approach which included all potential confounders. Third, our results may be subject to channelling bias arising from suggested concerns on NSAIDs. Although the direction of channelling bias is uncertain, we believe this bias to have directed the effect estimate towards the null as such concerns could affect clinicians to not prescribe NSAIDs to patients with poor prognosis when hospitalised with COVID-19. Finally, residual confounding from unmeasured confounders (e.g. smoking history, body mass index) may be present due to inherent limitations of claims data.

In summary, hospitalised patients with COVID-19 who received NSAIDs were associated with exacerbated COVID-19 and related outcomes compared to non-users. Hence, our findings support the suggested harms NSAIDs may have when used in COVID-19 patients. While awaiting the results of confirmatory studies, we suggest NSAIDs be used with caution as the harms associated with their use may outweigh their benefits among patients with COVID-19.

DISCLOSURES

ACKNOWLEDGEMENTS: The authors appreciate healthcare professionals dedicated to

treating COVID-19 patients in South Korea, and the Ministry of Health and Welfare, the Health

Insurance Review & Assessment Service, and Do-Yeon Cho of the Health Insurance Review

& Assessment Service of South Korea for sharing invaluable national health insurance claims

data in a prompt manner. JYS report receipt of research funding from the Ministry of Food and

Drug Safety, the Ministry of Health and Welfare, and the National Research Foundation of

South Korea; grants from pharmaceutical companies including Amgen, Pfizer, Hoffmann-La

Roche, Dong-A ST, Yungjin outside the submitted work, HEJ report receipt of research funding

from the National Research Foundation of Korea outside the submitted work, and KBF is

supported by a salary support award from the Fonds de recherche du Québec – santé (Quebec

Foundation for Health Research) and a William Dawson Scholar award from McGill University.

CONTRIBUTORS: All authors contributed to the study design and interpretation of the data.

HEJ and HL designed the study, interpreted the data. HEJ wrote the manuscript. HL conducted

the statistical analyses. HJS, YJC, and KBF interpreted the data and critically revised the

manuscript. All authors reviewed and commented on drafts and approved the final manuscript

and the decision to submit it for publication. JYS is the guarantor.

DECLARATION OF INTERESTS: All authors completed and submitted the ICMJE Form

for Disclosure of Potential Conflicts of Interest. The authors declare no competing interests.

DATA SHARING: No additional data available.

FUNDING: Government-wide R&D Fund for Infectious Disease Research.

15

REFERENCES

- World Health Organization. Coronavirus disease (COVID-19) Situation Dashboard.
 https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd
 (accessed 27 Apr 2020.
- 2. Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: a prospective contact-tracing study. *J Infect* 2020; **S0163-4453**(20): 30117-1.
- 3. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med* 2020.
- 4. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. . *Cell* 2020; **S0092-8674**(20): 30229-4.
- 5. Caughey G, Clelend L, Penglis P, Gamble J, James M. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective upregulation of prostacyclin synthesis by COX-2. *J Immunol* 2001; **167**(5): 2831.
- 6. Lee S, Cheung C-Y, Nicholls J, et al. Hyperinduction of Cyclooxygenase-2-Mediated Proinflammatory Cascade: A Mechanism for the Pathogenesis of Avian Influenza H5N1 Infection. *The Journal of infectious diseases* 2008; **198**(4): 525-35.
- 7. Fung S-Y, Yuen K-S, Ye Z-W, Chan C-P, Jin D-Y. A Tug-Of-War Between Severe Acute Respiratory Syndrome Coronavirus 2 and Host Antiviral Defence: Lessons From Other Pathogenic Viruses. *Emerg Microbes Infect* 2020; **9**(1): 558-70.
- 8. Emma. UPDATE Coronavirus: French health minister and WHO issue warning over taking anti-inflammatories. The Local France. 2020.
- 9. US Food and Drug Administration. FDA advises patients on use of non-steroidal anti-

inflammatory drugs (NSAIDs) for COVID-19. US Food and Drug Administration,. 2020.

- 10. European Medicines Agency. EMA gives advice on the use of non-steroidal antiinflammatories for COVID-19.: European Medicines Agency, 2020.
- 11. Therapeutic Goods Administration. No evidence to support claims ibuprofen worsens COVID-19 symptoms. Therapeutic Goods Administration,. 2020.
- 12. World Health Organization. Scientific Brief: The use of non-steroidal antiinflammatory drugs (NSAIDs) in patients with COVID-19. World Health Organization, 2020.
- 13. Health Insurance Review & Assessment Service, Ministry of Health and Welfare. #opendata4covid19. 2020. https://hira-covid19.net/ (accessed 15 Apr 2020.
- 14. Kim J, Yoon S, Kim L, Kim D. Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data. *J Korean Med Sci* 2017; **32**(5): 718-28.
- 15. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance. World Health Organization,. 2020.
- 16. Ministry of Health and Welfare RoK. About COVID-19: Patient Treatment & Management. 2020. http://ncov.mohw.go.kr/baroView3.do?brdId=4&brdGubun=43 (accessed 19 May 2020.
- 17. Desai R, Franklin J. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. *BMJ* 2019; **367**: 15657.
- 18. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the Twenty-sixth Annual SAS Users Group international conference; 2001. SAS Institute.
- 19. L'Agence nationale de sécurité du médicament et des produits de santé (ANSM). Anti-

inflammatoires non stéroïdiens (AINS) et complications infectieuses graves - Point d'Information. L'Agence nationale de sécurité du médicament et des produits de santé (ANSM),. 2019.

- 20. Voiriot G, Philippot Q, Elabbadi A, Elbim C, Chalumeau M, Fartoukh M. Risks Related to the Use of Non-Steroidal Anti-Inflammatory Drugs in Community-Acquired Pneumonia in Adult and Pediatric Patients. *J Clin Med* 2019; **8**(6).
- 21. Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ 2020.
- 22. Wen Y, Hsiao F, Chan K, Lin Z, Shen L, Fang C. Acute Respiratory Infection and Use of Nonsteroidal Anti-Inflammatory Drugs on Risk of Acute Myocardial Infarction: A Nationwide Case-Crossover Study. *The Journal of infectious diseases* 2017; **215**(4): 503-9.
- 23. Wen Y, Hsiao F, Lin Z, Fang C, Shen L. Risk of stroke associated with use of nonsteroidal anti-inflammatory drugs during acute respiratory infection episode. *Pharmacoepidemiology and drug safety* 2018; **27**(6): 645-51.
- 24. Schmidt M, Lamberts M, Olsen A, et al. Cardiovascular Safety of Non-Aspirin Non-Steroidal Anti-Inflammatory Drugs: Review and Position Paper by the Working Group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. *Eur Heart J* 2016; **37**(13): 1015-23.
- 25. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet (London, England)* 2013; **382**(9894): 769-79.
- 26. Clavé S, Rousset-Rouvière C, Daniel L, Tsimaratos M. The Invisible Threat of Non-steroidal Anti-inflammatory Drugs for Kidneys. *Front Pediatr* 2017; **7**: 520.
- 27. Zhang X, Donnan P, Bell S, Guthrie B. Non-steroidal Anti-Inflammatory Drug Induced Acute Kidney Injury in the Community Dwelling General Population and People With Chronic Kidney Disease: Systematic Review and Meta-Analysis. *BMC Nephrol* 2017; **18**(1): 256.

- 28. Qiao W, Wang C, Chen B, et al. Ibuprofen Attenuates Cardiac Fibrosis in Streptozotocin-Induced Diabetic Rats. *Cardiology* 2015; **131**(2): 97-106.
- 29. Li W, Moore M, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 2003; **426**(6965): 450-4.
- 30. Kuba K, Imai Y, Rao S, et al. A Crucial Role of Angiotensin Converting Enzyme 2 (ACE2) in SARS Coronavirus-Induced Lung Injury. *Nat Med* 2005; **11**(8): 875-9.
- 31. Bancos S, Bernard M, Topham D, Phipps R. Ibuprofen and Other Widely Used Non-Steroidal Anti-Inflammatory Drugs Inhibit Antibody Production in Human Cells. *Cell Immunol* 2009; **258**(1): 18-28.
- 32. Inaoka M, Kimishima M, Takahashi R, Shiohara T. Non-steroidal Anti-Inflammatory Drugs Selectively Inhibit Cytokine Production by NK Cells and Gamma Delta T Cells. *Exp Dermatol* 2006; **15**(12): 981-90.
- 33. Kyriacou D, Lewis R. Confounding by indication in clinical research. *JAMA* 2016; **316**(17): 1818-9.
- 34. Oh I, Filion K, Jeong H, Shin J. An empirical assessment of immeasurable time bias in the setting of nested case-control studies: Statins and all-cause mortality among patients with heart failure. *Pharmacoepidemiology and drug safety* 2019; **28**(10): 1318-27.
- 35. Health Insurance Review and Assessment Service. Evaluation and consideration methods of consistency between health insurance claims diagnostic codes and medical records: Health Insurance Review and Assessment Service, 2017.
- 36. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. *J Clin Epidemiol* 1994; **47**(7): 731-7.

FIGURE LEGENDS

Figure 1. Nationwide population-based cohort study design

Figure 2. Forest plot summarizing the risk of primary outcome* associated with NSAIDs when stratified for age, sex, formulation of NSAIDs and history of comorbidities

*Primary outcome include all-cause death, intensive care unit admission, mechanical ventilation use, sepsis

Figure 3. Forest plot summarizing the results of sensitivity analyses when comparing NSAIDs to paracetamol to minimize confounding by indication, or including non-hospitalised patients with COVID-19

Table 1. Baseline sociodemographic and clinical characteristics of adult patients hospitalised with COVID-19 in South Korea, as of Apr 8, 2020. Values are numbers (percentages) unless stated otherwise.

	Adult patients hospitalised	NCAID	NI	aSD	
	with COVID-19	NSAIDs user	Non-user	Before	After
	n=1,824 (%)	n=285 (%)	n=1,539 (%)	$\mathbf{IPTW}^{\mathbb{P}}$	IPTW [₽]
Age† (years; mean±std)	49.0 ± 19.0	54.4 ± 17.3	48.0 ± 19.2	0.47	0.15
<30	442 (24)	34 (12)	408 (27)		
30-39	191 (11)	26 (9)	165 (11)		
40-49	259 (14)	44 (15)	215 (14)		
50-59	357 (20)	60 (21)	297 (19)		
60-69	276 (15)	64 (23)	212 (14)		
70-79	197 (11)	38 (13)	159 (10)		
80-89	88 (5)	17 (6)	71 (5)		
≥90	14 (1)	2 (1)	12 (1)		
Sex [†]				0.07	0.19
Male	750 (41)	125 (44)	625 (41)		
Female	1,074 (59)	160 (56)	914 (59)		
Health insurance type [†]				0.07	0.19
National health insurance	1,661 (91)	246 (86)	1,415 (92)		
Medical aid	163 (9)	39 (14)	124 (8)		
Comorbidities [‡]					
Hypertension	371 (20)	81 (28)	290 (19)	0.23	0.01
Hyperlipidaemia	339 (19)	70 (25)	269 (18)	0.17	0.00
Diabetes mellitus	227 (12)	48 (17)	179 (12)	0.15	0.03
Malignancy	108 (6)	19 (7)	89 (6)	0.04	0.02
Asthma	116 (6)	21 (7)	95 (6)	0.05	0.01
COPD	291 (16)	49 (17)	242 (16)	0.04	0.00
Atherosclerosis	14 (1)	7 (3)	7 (1)	0.17	0.00
Chronic renal failure	33 (2)	3 (1)	30 (2)	0.07	0.01
Chronic liver disease	73 (4)	12 (4)	61 (4)	0.01	0.02
Rheumatoid arthritis	22 (1)	2 (1)	20 (1)	0.06	0.05
Osteoarthritis	295 (16)	72 (25)	223 (15)	0.27	0.02
Gastrointestinal conditions	1,100 (60)	197 (69)	903 (59)	0.22	0.02
Concomitant medications [‡]					
ACE inhibitors/ARBs	318 (17)	64 (23)	254 (17)	0.15	0.01
β-blockers	184 (10)	39 (14)	145 (9)	0.13	0.01
Calcium channel blockers	277 (15)	63 (22)	214 (14)	0.22	0.02
Diuretics	118 (7)	26 (9)	92 (6)	0.12	0.01
Nitrates	41 (2)	8 (3)	33 (2)	0.04	0.02

Note: ACE=angiotensin converting enzyme. ARB=angiotensin-receptor II blocker. aSD=absolute standardized difference. COPD=chronic obstructive pulmonary disease. IPTW=inverse probability of treatment weight. NSAIDs=nonsteroidal anti-inflammatory drugs. std=standard deviation.

[†]Assessed on cohort entry (date of hospitalisation with COVID-19)

[‡]Assessed in the year prior to cohort entry

IPTW adjusted cohort, where the propensity score was estimated by including age, sex, health insurance type, comorbidities (hypertension, hyperlipidaemia, diabetes mellitus, asthma, chronic obstructive pulmonary disease, malignancy, atherosclerosis, chronic renal failure, chronic liver disease, rheumatoid arthritis, osteoarthritis, gastrointestinal conditions), and co-medications (angiotensin converting enzyme inhibitors, angiotensin-receptor II blockers, β-blockers, calcium channel blockers, diuretics, nitrates) in the multivariable logistic regression model (c-statistics: 0.655 for NSAIDs users and non-users)

Table 2. Risk of adverse clinical outcomes associated with NSAIDs users compared with non-users among adult patients hospitalised with COVID-19

	Number	Number	Event	Odds ratio (95% confidence interval)				
	of patients	of events	rates (%)	Unadjusted*	Model Adjusted [†]	IPTW Adjusted‡		
All-cause death, ICU admission, mechanical ventilation use, sepsis								
Non-users	1,539	56	3.6	1.00 (reference)	1.00 (reference)	1.00 (reference)		
NSAIDs users	285	19	6.7	1.89 (1.11-3.24)	1.53 (0.86-2.72)	1.54 (1.11-2.15)		
Cardiovascular or 1	renal complication	ons ^p						
Non-users	1,539	29	1.9	1.00 (reference)	1.00 (reference)	1.00 (reference)		
NSAIDs users	285	15	5.3	2.89 (1.53-5.47)	2.42 (1.20-4.91)	2.64 (1.67-4.16)		


Note: ICU=intensive care unit. IPTW=inverse probability of treatment weight. NSAIDs=nonsteroidal anti-inflammatory drugs.

‡IPTW adjusted multivariable logistic regression model (main model), where the propensity score used was estimated by including age, sex, health insurance type, comorbidities (hypertension, hyperlipidaemia, diabetes mellitus, asthma, chronic obstructive pulmonary disease, malignancy, atherosclerosis, chronic renal failure, chronic liver disease, rheumatoid arthritis, osteoarthritis, gastrointestinal conditions), and co-medications (angiotensin converting enzyme inhibitors, angiotensin-receptor II blockers, b-blockers, calcium channel blockers, diuretics, nitrates) in the multivariable logistic regression model (*c*-statistics: 0.655 for NSAIDs users and non-users)

*Cardiovascular or renal complications include myocardial infarction, heart failure, stroke, acute renal failure

^{*}Unadjusted univariable logistic regression model

[†]Fully adjusted multivariable logistic regression model with all potential confounders including age, sex, health insurance type, comorbidities (hypertension, hyperlipidaemia, diabetes mellitus, asthma, chronic obstructive pulmonary disease, malignancy, atherosclerosis, chronic renal failure, chronic liver disease, rheumatoid arthritis, osteoarthritis, gastrointestinal conditions), and co-medications (angiotensin converting enzyme inhibitors, angiotensin-receptor II blockers, calcium channel blockers, diuretics, nitrates)



Note: HIRA=Health Insurance Review and Assessment Service. NSAIDs=nonsteroidal anti-inflammatory drugs.

The HIRA database of South Korea contains insurance benefit claims and longitudinal history of all medical services from the entire Korean population of 50 million inhabitants, based on fee-for-service payment system; thus, data from both inpatient and outpatient settings are available. A cohort of adult patients hospitalised with COVID-19 were identified from confirmed cases of COVID-19. Patients prescribed NSAIDs while hospitalised were classified as NSAIDs users and those not prescribed NSAIDs were classified as non-users. We assessed the risk of death, intensive care unit admission, mechanical ventilation use, or sepsis associated with NSAIDs users compared to non-users

Figure 1. Nationwide population-based cohort study design

	Number	Event rates (%)		IPTW adjusted odds ratio [†]		_
	of Patients	NSAIDs	Non-users	(95% confidence inter	P interaction	
Formulation of NSAIDs						
Oral formulations [‡]	1,715	5.7	3.6	1.31	(0.88-1.95)	0.2721
Intravenous formulations	1,648	8.3	3.6	1.90	(1.24-2.90)	0.2731
Age group (years)						
<45	750	2.5	1.8	1.39	(0.60-3.21)	
45-64	649	9.0	2.9	4.34	(2.28-8.24)	0.2558
≥65	425	7.2	8.5	0.69	(0.39-1.24)	
Sex						
Male	750	10.4	5.3	1.40	(0.88-2.21)	0.8193
Female	1,074	3.8	2.5	1.41	(0.80-2.48)	0.8193
History of hypertension						
Yes	371	12.4	7.6	1.95	(1.09-3.49)	0.8782
No	1,453	4.4	2.7	1.59	(1.02-2.48)	0.8782
History of hyperlipidaemia						
Yes	339	8.6	4.5	1.47	(0.57-3.76)	0.6944
No	1,485	6.1	3.5	1.43	(0.98-2.08)	0.0944
History of diabetes mellitus						
Yes	227	6.3	6.2	0.46	(0.13-1.61)	0.2526
No	1,597	6.8	3.3	1.57	(1.08-2.29)	0.3536
				0.1 1.0 10.0		

Note: IPTW=inverse probability of treatment weight. NSAIDs=nonsteroidal anti-inflammatory drugs.

Figure 2. Forest plot summarizing the risk of primary outcome* associated with NSAIDs when stratified for age, sex, formulation of NSAIDs and history of comorbidities

^{*}Primary outcome includes all-cause death, intensive care unit admission, mechanical ventilation use, sepsis

^{*}IPTW adjusted multivariable logistic regression model, where the propensity score used was estimated by including age, sex, health insurance type, comorbidities (hypertension, hyperlipidaemia, diabetes mellitus, asthma, chronic obstructive pulmonary disease, malignancy, atherosclerosis, chronic renal failure, chronic liver disease, rheumatoid arthritis, osteoarthritis, gastrointestinal conditions), and co-medications (angiotensin converting enzyme inhibitors, angiotensin-receptor II blockers, calcium channel blockers, diuretics, nitrates) in the multivariable logistic regression model

[‡]Comparing patients prescribed oral formulation of NSAIDs to non-users

Comparing patients prescribed intravenous formulation of NSAIDs to non-users

	Number	Event rates (%)			IPTW adjusted odds ratio [†]		
	of Patients	NSAIDs	Reference	•	(95% confidence		
All-cause death, ICU admission, mechanica	l ventilation use	e, sepsis					
Hospitalised COVID-19 patients							
NSAIDs users vs. non-users	1,824	6.7	3.6		-	1.54	(1.11-2.15)
NSAIDs users vs. paracetamol users	1,230	6.7	4.0		+-	1.31	(0.89-1.95)
All COVID-19 patients [‡]							
NSAIDs users vs. non-users	5,358	2.9	1.4		—	1.67	(1.25-2.25)
Cardiovascular or renal complications							
Hospitalised COVID-19 patients							
NSAIDs users vs. non-users	1,824	5.2	1.9		-	2.64	(1.67-4.16)
NSAIDs users vs. paracetamol users	1,230	5.2	1.5		-	2.68	(1.51-4.75)
All COVID-19 patients [‡]							
NSAIDs users vs. non-users	5,358	2.5	1.2		-	2.37	(1.71-3.30)
				0.2	1.0 5.0		

Note: ICU=intensive care unit. IPTW=inverse probability of treatment weight. NSAIDs=nonsteroidal anti-inflammatory drugs.

Figure 3. Forest plot summarizing the results of sensitivity analyses when comparing NSAIDs to paracetamol to minimize confounding by indication, or including non-hospitalised patients with COVID-19

IPTW adjusted multivariable logistic regression model, where the propensity score used was estimated by including age, sex, health insurance type, comorbidities (hypertension, hyperlipidaemia, diabetes mellitus, asthma, chronic obstructive pulmonary disease, malignancy, atherosclerosis, chronic renal failure, chronic liver disease, rheumatoid arthritis, osteoarthritis, gastrointestinal conditions), and co-medications (angiotensin converting enzyme inhibitors, angiotensin-receptor II blockers, calcium channel blockers, diuretics, nitrates) in the multivariable logistic regression model

[‡]Patients diagnosed with COVID-19 after receiving positive test results for COVID-19

Cardiovascular or renal complications include myocardial infarction, heart failure, stroke, acute renal failure